Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection

Clin Infect Dis. 2018 Jan 6;66(2):289-292. doi: 10.1093/cid/cix787.

Abstract

We assessed the effectiveness and safety of sofosbuvir (SOF) combined with ledipasvir (LDV) or daclatasvir (DCV) in 12 heart transplant recipients with chronic hepatitis C virus (HCV). The sustained virologic response (SVR12) rate was 100% [95% confidence interval [CI]: 75.8%-100%]. All patients tolerated treatment well without interruption, death, or serious adverse events.

Keywords: direct acting antiviral agent; heart transplantation; hepatitis C virus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Benzimidazoles / adverse effects
  • Benzimidazoles / therapeutic use*
  • Carbamates
  • Drug Therapy, Combination / adverse effects
  • Drug Therapy, Combination / methods
  • Drug-Related Side Effects and Adverse Reactions / epidemiology
  • Drug-Related Side Effects and Adverse Reactions / pathology
  • Female
  • Fluorenes / adverse effects
  • Fluorenes / therapeutic use*
  • Heart Transplantation*
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Imidazoles / adverse effects
  • Imidazoles / therapeutic use*
  • Male
  • Middle Aged
  • Prospective Studies
  • Pyrrolidines
  • Sofosbuvir / adverse effects
  • Sofosbuvir / therapeutic use*
  • Sustained Virologic Response
  • Transplant Recipients*
  • Treatment Outcome
  • Valine / analogs & derivatives
  • Young Adult

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Carbamates
  • Fluorenes
  • Imidazoles
  • Pyrrolidines
  • ledipasvir
  • Valine
  • daclatasvir
  • Sofosbuvir